| Authors: |
Chmielewska N; Department of Experimental and Clinical Neuroscience, Institute of Psychiatry and Neurology, Sobieskiego 9 Street, 02-957 Warsaw, Poland. Electronic address: nchmielewska@ipin.edu.pl., Wicik Z; Department of Experimental and Clinical Neuroscience, Institute of Psychiatry and Neurology, Sobieskiego 9 Street, 02-957 Warsaw, Poland. Electronic address: zwicik@ipin.edu.pl., Kearns IR; Epilepsy Therapy Screening Program Contract Site, Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, UT, USA. Electronic address: ireland.kearns@utah.edu., Palmer CW; Epilepsy Therapy Screening Program Contract Site, Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, UT, USA. Electronic address: cory.palmer@pharm.utah.edu., Vasquez G; Epilepsy Therapy Screening Program Contract Site, Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, UT, USA. Electronic address: gustavo.vasquez@hsc.utah.edu., Pruess T; Epilepsy Therapy Screening Program Contract Site, Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, UT, USA. Electronic address: t.pruess@utah.edu., Camacho J; Epilepsy Therapy Screening Program Contract Site, Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, UT, USA. Electronic address: janintca@buffalo.edu., Metcalf CS; Epilepsy Therapy Screening Program Contract Site, Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, UT, USA. Electronic address: cameron.s.metcalf@utah.edu. |
